Vor Biopharma Inc.
VOR · Biotech · Nasdaq · As of 10 Sep 2026
- FundamentalsNot enough data yet
- ValueNot enough data yet
- News flowBalanced
- MomentumBalanced
- SafetyBalanced
Overall confidence 41/100 — few inputs available yet
Fundamental score not available. AIR's fundamental engine is built for businesses with established revenue and cash flow; biotech financial profiles — often R&D-heavy or pre-revenue — don't yet fit the measures it requires. AIR still assesses this company on discovery, market confirmation and risk, at reduced overall confidence.
Discovery Gap: Very high (64/100) · Gap confidence 66/100Documented progress is running well ahead of market attention.
This month at a glance
AIR Score™ change: -1Slipped -1 on softer inputs.
Cycle window9 Sep 2026 → 10 Sep 2026
Momentum-1Weighed on the latest score.
Evidence timeline
- [8-K 5.02] Vor Biopharma Inc. — Departure/Election of Directors or Principal OfficersSEC · SEC EDGARJul 6, 2026 · 8-K
- [8-K 3.02] Vor Biopharma Inc. — Unregistered Sales of Equity SecuritiesSEC · SEC EDGARMar 26, 2026 · 8-K
- [8-K 1.01] Vor Biopharma Inc. — Entry into a Material Definitive AgreementSEC · SEC EDGARMar 26, 2026 · 8-K
- [8-K 2.02] Vor Biopharma Inc. — Results of Operations and Financial ConditionSEC · SEC EDGARJan 12, 2026 · 8-K
- [8-K 5.02] Vor Biopharma Inc. — Departure/Election of Directors or Principal OfficersSEC · SEC EDGARDec 31, 2025 · 8-K
- [8-K 3.02] Vor Biopharma Inc. — Unregistered Sales of Equity SecuritiesSEC · SEC EDGARDec 15, 2025 · 8-K
- [8-K 1.01] Vor Biopharma Inc. — Entry into a Material Definitive AgreementSEC · SEC EDGARDec 15, 2025 · 8-K
- [8-K 5.02] Vor Biopharma Inc. — Departure/Election of Directors or Principal OfficersSEC · SEC EDGARDec 15, 2025 · 8-K
- [8-K 5.02] Vor Biopharma Inc. — Departure/Election of Directors or Principal OfficersSEC · SEC EDGARDec 5, 2025 · 8-K
- [8-K 8.01] Vor Biopharma Inc. — Other EventsSEC · SEC EDGARNov 10, 2025 · 8-K
- [8-K 5.02] Vor Biopharma Inc. — Departure/Election of Directors or Principal OfficersSEC · SEC EDGARNov 2, 2025 · 8-K
- [8-K 3.03] Vor Biopharma Inc. — Material Modification to Rights of Security HoldersSEC · SEC EDGARSep 17, 2025 · 8-K
Ask AIR
What would change our view
A weaker balance sheet in the next filing cycle, a material regulatory setback, or attention arriving — which closes the gap by design would move the score, and the page would show which one did.
Research, not tips. No buy/sell recommendations, no price forecasts. Every score is derived from public filings and market data — figures round to whole numbers and refresh each trading day.